DSIP Research: What the Published Literature Has Investigated

What is DSIP?

What is DSIP? DSIP (delta sleep-inducing peptide) is a nonapeptide — nine amino acids, sequence Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu (WAGGDASGE), molecular weight approximately 849. It was first isolated and characterised by Schoenenberger and Monnier in Basel from the cerebral venous blood of rabbits during electrically-induced sleep, and named for the enhancement of delta (slow-wave) EEG activity they reported after intraventricular infusion (Schoenenberger & Monnier, PNAS 1977). That is a neutral molecular and historical definition; the sections below describe what researchers examined, not effects in people.

Molecule properties

DSIP is a nine-residue peptide (WAGGDASGE) with a molecular weight of roughly 849, supplied for research as a lyophilized powder — which is why it is catalogued as a research peptide. The literature describes a reported instability and rapid degradation of DSIP in plasma and serum (work associated with the Kastin group), and there is a distinction between endogenous DSIP and the synthetic, research-grade material used in studies. Unusually for a peptide first described five decades ago, no encoding gene, precursor protein, or specific receptor has ever been identified for DSIP. These are molecule and biochemistry facts only — no handling or reconstitution guidance.

Discovery and the “unresolved riddle”

The discovery narrative is the most defensible and most interesting content on this page. Schoenenberger and Monnier dialysed blood from the cerebral circulation of rabbits whose intralaminar thalamus was electrically stimulated to induce sleep, then infused the dialysate into recipient rabbits and reported increased delta-wave EEG activity (Schoenenberger & Monnier 1977). Stated plainly: despite the peptide having been sequenced and synthesised in the 1970s, the decades that followed did not resolve its biology. Kovalzon’s review names the problem in its own title — DSIP as “a still unresolved riddle” (J Neurochem 2006) — noting no confirmed gene, precursor or receptor, and observing that much reported “DSIP-like immunoreactivity” may reflect distinct endogenous peptides rather than DSIP itself. This section carries the honesty load: the foundational finding on delta EEG has not been robustly reproduced, and DSIP’s endogenous role remains undefined. A famous name and an old paper are not the same thing as a settled mechanism.

Mechanisms and effects researchers have examined

The DSIP mechanism literature is heterogeneous, dated, and largely unreplicated. Each direction below is framed as what researchers examined, in the past, and every one carries the same caveat that these are historical research observations rather than effects available to a reader:

• Delta (slow-wave) EEG / sleep architecture — the original characterisation reported enhanced delta and spindle EEG in rabbits after intraventricular infusion (Schoenenberger & Monnier 1977). The Graf & Kastin reviews summarise reported sleep-related observations across rabbits, rats, mice and small human work, noting a U-shaped dose-response and a more REM-oriented effect in cats (Neurosci Biobehav Rev 1984). These are historical research observations only.
• Stress / HPA-axis signalling — Graf, Kastin, Coy & Fischman reported that DSIP attenuated CRF-induced corticosterone release at the pituitary level in rodents, with no effect when ACTH was given directly (Neuroendocrinology 1985). A rodent neuroendocrine observation, not a stress claim.
• Multivariate / pleiotropic effects — the Graf & Kastin reviews catalogue reported effects on circadian and locomotor patterns, neurotransmitter levels, thermoregulation, and drug-withdrawal phenomena — explicitly a heterogeneous and inconsistent literature (Peptides 1986).

The section closes as the literature does: DSIP is an early neuropeptide whose reported effects are broad, inconsistent, and mechanistically unexplained; no defined receptor or signalling pathway is established. Each bullet names something investigated, not an effect in a reader.

Research models and the limits of the evidence

The preclinical models behind DSIP are the rabbit of the original discovery and later rat and mouse EEG and neuroendocrine studies. Human-relevant material is limited to small early clinical reports from the 1980s — for example an open pilot study in chronic-pain patients (Larbig et al., Eur Neurol 1984) and an open series in alcohol and opiate withdrawal (Dick et al., Eur Neurol 1984). Described accurately, these are dated, small, mostly open-label reports that were never reproduced in large randomised controlled trials; their claimed outcomes are not restated here as effects, and they do not mean a reader would experience anything.

It bears repeating because the peptide’s name recognition outruns its evidence: the overall evidence base is old, sparse, methodologically weak, and largely unreplicated, and modern reviews regard DSIP’s biology as unresolved. This is a genuinely low-literature compound relative to how often it is discussed. The honest response is to say so rather than to inflate the record — which is why the mechanisms above are reported as what was investigated rather than what was concluded about people, and why the citations point back to the named studies so a reader can weigh the age and design of each one directly.

DSIP among early neuropeptides

As a matter of research history, DSIP is one of the first putative endogenous sleep- and regulatory-peptides, sitting alongside other CNS-signalling research peptides in the broad family of small neuroactive peptides. What makes it a distinctive — and cautionary — research target is precisely its combination of fame, age and unresolved biology: named in the 1970s, still without a defined receptor. For another Russian-lineage CNS research peptide with its own literature, see Selank research; and for a related regulatory-peptide explainer where a discrete literature exists, see Epitalon research. This is family and research-focus context only — no stacking or use advice.

Research-grade sourcing and verification

For laboratory research use only, DSIP is supplied with a per-batch Certificate of Analysis reporting HPLC purity (%) and mass-spec identity confirmation — assurances that matter especially given DSIP’s reported handling sensitivity and the prevalence of mislabelled product in this category. Check the exact batch on the self-serve verify tool, and see how to read a COA for what the certificate reports. This is identity and purity framing for research use only, not an outcome.

Frequently asked questions

Literature cited

1. Schoenenberger GA, Monnier M. “Characterization of a delta-electroencephalogram (-sleep)-inducing peptide.” Proc Natl Acad Sci USA. 1977;74(3):1282–6. PMID 265572.
2. Graf MV, Kastin AJ. “Delta-sleep-inducing peptide (DSIP): a review.” Neurosci Biobehav Rev. 1984;8(1):83–93. PMID 6145137.
3. Graf MV, Kastin AJ. “Delta-sleep-inducing peptide (DSIP): an update.” Peptides. 1986;7(6):1165–87. PMID 3550726.
4. Graf MV, Kastin AJ, Coy DH, Fischman AJ. “Delta-sleep-inducing peptide reduces CRF-induced corticosterone release.” Neuroendocrinology. 1985;41(4):353–6. PMID 2995861.
5. Kovalzon VM. “Delta sleep-inducing peptide (DSIP): a still unresolved riddle.” J Neurochem. 2006;97(2):303–9.
6. Larbig W, et al. “Therapeutic effects of delta-sleep-inducing peptide (DSIP) in patients with chronic, pronounced pain episodes. A clinical pilot study.” Eur Neurol. 1984. PMID 6548970.
7. Dick P, et al. “Successful treatment of withdrawal symptoms with delta sleep-inducing peptide.” Eur Neurol. 1984. PMID 6328354.